OncLive Staff

Articles

Camidge and Farmen Discuss the Nuances of Cancer Care and Patient Advocacy

March 4th 2024

Camidge and Farmen talk through patient advocacy, Farmen’s cancer diagnosis, and the people who rallied around Farmen during the early days of her disease.

Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice

February 29th 2024

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma and his anticipated use of the agent.

Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

February 26th 2024

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference

February 22nd 2024

Dr Tripathy discusses the unique aspects of the Miami Breast Cancer Conference that make it worth returning to year after year.

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

February 19th 2024

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

Camidge and Kelley Share the Details of Practicing Within Various Health Care Models

February 15th 2024

Drs Camidge and Kelley discuss the ways Dr Kelley’s passion for research guided his early career path.

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

February 12th 2024

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

February 8th 2024

Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges and growth opportunities they have experienced throughout their careers.

Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment

February 5th 2024

Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.

Camidge and Okuyama Sasaki Highlight How Safety Net Hospitals Widen the Scope of Cancer Care

February 1st 2024

Drs Camidge and Okuyama Sasaki discuss the goals of safety net hospitals and the dynamics of helping low-income patients access cancer treatments.

Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma

January 29th 2024

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

January 25th 2024

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Lunning and Maddocks Talk Through Frontline MCL Management

January 22nd 2024

Drs Lunning and Maddocks discuss the management of MCL in the up-front setting.

Camidge and Leland Discuss the Road to a Multifaceted Biotechnology Career

January 18th 2024

Drs Camidge and Leland discuss various roles in the biotechnology field and the intricacies of starting a biotechnology company.

FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment

January 15th 2024

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management

January 8th 2024

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

January 4th 2024

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC

January 1st 2024

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.